Opinion|Videos|January 1, 2025
Examining Elafibranor as a Treatment Option for PBC
Panelists discuss how elafibranor demonstrated significant efficacy in the ELATIVE trial, which strengthens confidence in its role as a long-term treatment option for patients with primary biliary cholangitis (PBC) who inadequately respond to ursodeoxycholic acid.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Elafibranor received accelerated approval based on findings from the
ELATIVE study. What are the key efficacy insights from this trial? - Elafibranor was also demonstrated to have long-term safety and efficacy at 3 years. How does this durability affect your clinical decision-making?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Q&A: How Pharmacists Can Address Structural Barriers in Obesity Care
5